Galectin Therapeutics
GALT
70 hedge funds and large institutions have $28.2M invested in Galectin Therapeutics in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 23 reducing their positions, and 14 closing their positions.
132% more call options, than puts
Call options by funds: $2.84M | Put options by funds: $1.23M
11% more capital invested
Capital invested by funds: $25.3M → $28.2M (+$2.9M)
1.33% less ownership
Funds ownership: 13.62% → 12.29% (-1.3%)
7% less funds holding
Funds holding: 75 → 70 (-5)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
48% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$447K |
| 2 |
KeyBank National Association
Cleveland,
Ohio
|
+$339K |
| 3 |
Capstone Investment Advisors
New York
|
+$143K |
| 4 |
QAM
QCI Asset Management
Pittsford,
New York
|
+$102K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$82.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$1.22M |
| 2 |
Millennium Management
New York
|
-$740K |
| 3 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$316K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$152K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$135K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Jane Street
New York
| – | -$37.7K | -11,133 | Closed |
|
|
BFM
77
Boothbay Fund Management
New York
| – | -$35K | -10,965 | Closed |
|
|
PCM
78
Pinz Capital Management
New York
| – | -$20K | -6,300 | Closed |
|
|
OSAM
79
O'Shaughnessy Asset Management
Stamford,
Connecticut
| – | -$18K | -5,655 | Closed |
|
80
Citigroup
New York
| – | -$2K | -557 | Closed |
|
81
New York State Common Retirement Fund
Albany,
New York
| – | -$1K | -259 | Closed |
|
82
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$1K | -213 | Closed |
|
83
Fidelity Investments
Boston,
Massachusetts
| – | +$149 | +44 | +4,400% |
|
GALT Hedge Fund Activity: Q3 2021 in Review
70 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2021, worth a combined $28.2M — up 11% from $25.3M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of GALT and 9 opened new positions — a net loss of 5 holders — while 23 trimmed existing stakes and 12 added.
The largest buyer was Geode Capital Management, adding an estimated $447K. The largest seller was Renaissance Technologies, cutting an estimated $1.22M.
- 70 institutional investors held Galectin Therapeutics (GALT) as of Q3 2021, down from 75 in Q2 2021.
- Funds reported $28.2M of Galectin Therapeutics stock for Q3 2021, up 11% quarter-over-quarter.
- 9 funds opened new Galectin Therapeutics positions in Q3 2021 and 14 closed out, a net change of -5 holders.
- The largest Galectin Therapeutics buyer in Q3 2021 was Geode Capital Management, an estimated $447K added.
- The largest Galectin Therapeutics seller in Q3 2021 was Renaissance Technologies, an estimated $1.22M sold.
Based on aggregated 13F filings for Q3 2021.